A series of articles has been created by HHS Research which shine the spotlight on studies published in 2014 with an HHS Researcher as lead author. Each piece features a study published in a journal with an Impact Factor greater than 10 and provides information about the author and about the research they lead. If their work strikes a cord with you, Tweet us at @HamHealthSc and include hashtag: HHSResearch
Dr. Hertzel Gerstein MD (Toronto), MSc. (McMaster), DABIM, FRCPC is Director of the Diabetes Care and Research program at Hamilton Health Sciences, Deputy Director, Population Health Research Institute, Population Health Research Institute Chair in Diabetes Research, Endocrinologist and Professor, Department of Medicine/ Department of Clinical Epidemiology and Biostatistics, Director, Division of Endocrinology & Metabolism, Head, Service of Endocrinology and Metabolism, Associate Editor for ACP Journal Club, and is on the editorial board of the Journal of Diabetes and Lancet Diabetes and Endocrinology. Dr. Gerstein’s academic interests include: a) using population health approaches to reduce the burden of diabetes in society and to prevent new diabetes; b) measuring the burden of diabetes in Canada; c) using epidemiologic approaches to study the relationship between dysglycemia, diabetes and cardiovascular disease; and d) clinical trials in the prevention & therapy of dysglycemia, diabetes and their consequences. Dr. Gerstein has published more than 300 papers, editorials and commentaries, and co-edited the textbook, Evidence-Based Diabetes Care
Gerstein, H. (2014). Effects of intensive glycaemic control on ischaemic heart disease: Analysis of data from the randomised, controlled ACCORD Trial. Lancet, 384, 1936-1941.
Background of study: Hyperglycaemia could substantially increase the risk of ischaemic heart disease in patients with type 2 diabetes. An investigation was conducted as to whether intensive lowering of glucose concentrations affects risk.
Interpretation: Raised glucose concentration is a modifiable risk factor for ischaemic heart disease in middle-aged people with type 2 diabetes and other cardiovascular risk factors.